2015 ASCO Annual Meeting: New Data in 10 Different Cancers from Merck’s Rapidly Expanding Immuno-Oncology Research Program for KEYTRUDA® (pembrolizumab) to be Presented

Dateline City: KENILWORTH, N.J. New Findings Show Anti-tumor Activity of KEYTRUDA in Five Additional Cancers: Colorectal, Esophageal, Ovarian, Renal Cell Carcinoma and Small-Cell Lung Cancer First-Time Presentations of DNA Mismatch Repair Deficiency Data in Colorectal and other Cancers and Nanostring RNA Data in Melanoma, Head and Neck and Gastric Cancers Industry-leading Number of PD-1 Clinical Trials Resulting in Growing Body of Data for KEYTRUDA across 13 Tumor Types KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that new investigational data in 10 different types of cancer from the company’s immuno-oncology development program evaluating its anti-PD-1 therapy, KEYTRUDA® (pembrolizumab), will be presented at the 51st Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago, May 29 – June 2, 2015. Language: English Contact: MerckMedia:Pamela Eisele, 267-305-3558Claire Mulhearn, 908-236-1118orInvestors:Joseph Romanelli, 908-740-1986Justin Holko, 908-740-1879 Ticker Slug: ...
Source: Merck.com - Corporate News - Category: Pharmaceuticals Tags: Oncology Newsroom Corporate News Latest News Source Type: news